摘要
目的:探讨白介素-1β(IL-1β)在急性冠脉综合征(ACS)发病中的作用,以及他汀类药物在ACS治疗中的抗炎作用。方法:75名ACS患者随机分为A、B、C三组,每组25人。A组为常规治疗组,B组为常规治疗+洛伐他汀20mg／d,C组为常规治疗+洛伐他汀40mg／d。均随访2周。以稳定性心绞痛(SAP)患者(n=25)为对照组。于治疗前、后分别测定血清IL-1β,并分析IL-1β与冠心病其他危险因素(TG、LDL-C)的相关性。结果:ACS组血清IL-1β水平明显高于SAP组(P<0．001),B、C组洛伐他汀早期干预治疗后血清IL-1β水平明显下降(P< 0．01),且呈剂量依赖性,而与TG、LDL-C下降无相关性。A组治疗前后无明显变化。结论:炎症反应是导致ACS 发生的原因之一,洛伐他汀治疗可显著降低ACS患者IL-1β水平,且与血脂的下降不相关,说明具有独立于降脂的抗炎作用。
Objective, To explore the role of interleukin 1β （IL-1β） in acute coronary syndrome （ACS） and the antiinflammatory effect of statin in the early treating ACS. Methods, The 75 ACS patients were randomly assigned to the A, B, C group, every group including 25 patients. A group was given the routine treatments; Based on the routine treatments, B group was given Lovastatin 20 mg/d; C group was given lovastatin 40 mg/d. A course of treatment was two-week. The 25 patients with stable angina （SAP）were regarded as control group. Before and after intervention with lovastatin, the serum IL-1β was measured. Results： IL-1β level was significantly higher in ACS group than that in SA group （P〈0. 001）. After two-week treatment with lovastatin, IL-1β levels decreased significantly in B and C group （P〈0.01） and it was dose-dependence （P〈0. 05）, but there was not correlation between the serum IL -1β and serum lipids levels docreased （P〉0. 05）. No significant changes were observed in A group （P〉0.05）. Conclusion： The inflammation reaction in the initiation of ACS may be one of the causes. Lovastatin can significantly decrease the IL-1β level, but the IL-1β level decrease no correlates with serum lipids level decrease.
出处
《心血管康复医学杂志》
CAS
2006年第1期55-57,61,共4页
Chinese Journal of Cardiovascular Rehabilitation Medicine
